Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12934024 | 0.92 | EDNRA (0.85) | EDNRAEDNRB | |
| SCHEMBL7949152 | 0.89 | EDNRA (0.81) | EDNRAEDNRB | |
| SCHEMBL5208967 | 0.88 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL3634612 | 0.88 | EDNRA (1.00) | EDNRAEDNRB | |
| P-Xylene SCHEMBL27465595 | 0.87 | EDNRA (0.78) | EDNRAEDNRB | |
| SCHEMBL6151342 | 0.86 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL4663316 | 0.86 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL6150873 | 0.85 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL4113628 | 0.85 | EDNRA (0.77) | EDNRAEDNRB | |
| SCHEMBL6588138 | 0.85 | EDNRA (0.80) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2810943-B1 | SITAXENTAN DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-09-27 | — | — | EP | disclosed |
| EP-2227453-B1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMA (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2810943-A1 | SITAXSENTAN DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-8592470-B2 | Sitaxentan derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8519137-B2 | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130197045-A1 | SITAXENTAN DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20130197045-A1 | SITAXENTAN DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20130197045-A1 | SITAXENTAN DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-7863308-B2 | Substituted thiophenes | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863308-B2 | Substituted thiophenes | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-5962490-A | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0699191-B1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORP (US) | 1998-12-16 | — | — | EP | disclosed |
| WO-1998049162-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| CN-1184470-A | Thienyl-, Furyl-, Pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORP (US) | 1998-06-10 | — | — | CN | disclosed |
| WO-1998013366-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-04-02 | — | — | WO | disclosed |
| EP-0819125-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-01-21 | — | — | EP | disclosed |
| US-5594021-A | VASOCONSTRICTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996031492-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197045-A1 | SITAXENTAN DERIVATIVE | CYP4A11, CYP11B1, HSD11B1 | EDNRA 84/4885EDNRB 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.